Lilly Shanahan, PhD1,2; William E. Copeland, PhD3
doi : 10.1001/jamapsychiatry.2021.0256
JAMA Psychiatry. 2021;78(7):695-696
Mary L. Phillips, MD1; Kenneth S. Kendler, MD2,3
doi : 10.1001/jamapsychiatry.2021.0022
JAMA Psychiatry. 2021;78(7):697-698
Murat Yücel, PhD1; Rico S. C. Lee, PhD1; Leonardo F. Fontenelle, MD1,2
doi : 10.1001/jamapsychiatry.2021.0243
JAMA Psychiatry. 2021;78(7):699-700
Eric C. Strain, MD1; Kyle M. Kampman, MD2; Roger D. Weiss, MD3
doi : 10.1001/jamapsychiatry.2021.0259
JAMA Psychiatry. 2021;78(7):701-702
Opemipo Akerele, BS; Madison McCall, BS; Gowri Aragam, MD
doi : 10.1001/jamapsychiatry.2021.0537
JAMA Psychiatry. 2021;78(7):703-704
Martina Nordh, PhD1; Tove Wahlund, PhD1; Maral Jolstedt, PhD1; Hanna Sahlin, PhD1; Johan Bjureberg, PhD1; Johan Ahlen, PhD1,2; Maria Lalouni, PhD1,3; Sigrid Salomonsson, PhD1; Sarah Vigerland, PhD1; Malin Lavner, MSc1; Lars-G?ran ?st, PhD4; Fabian Lenhard, PhD1; Hugo Hesser, PhD5,6; David Mataix-Cols, PhD1; Jens H?gstr?m, PhD1; Eva Serlachius, MD, PhD1
doi : 10.1001/jamapsychiatry.2021.0469
JAMA Psychiatry. 2021;78(7):705-713
Social anxiety disorder (SAD) is a prevalent childhood-onset disorder associated with lifelong adversity and high costs for the individual and society at large. Cognitive behavioral therapy (CBT) is an established evidence-based treatment for SAD, but its availability is limited.
Philippa Garety, PhD1,2; Thomas Ward, PhD1,2; Richard Emsley, PhD3; Kathryn Greenwood, PhD4,5; Daniel Freeman, PhD6,7; David Fowler, MSc4,5; Elizabeth Kuipers, PhD1,2; Paul Bebbington, PhD8; Mar Rus-Calafell, PhD6,7,9; Alison McGourty, DPsych5; Catarina Sacadura, PsyD5; Nicola Collett, DClinPsy6,7,10; Kirsty James, MSc3; Amy Hardy, PhD1,2
doi : 10.1001/jamapsychiatry.2021.0326
JAMA Psychiatry. 2021;78(7):714-725
Persistent paranoia is common among patients with psychosis. Cognitive-behavioral therapy for psychosis can be effective. However, challenges in engagement and effectiveness remain.
R. Yates Coley, PhD1,2; Eric Johnson, MS1; Gregory E. Simon, MD, MPH1; Maricela Cruz, PhD1; Susan M. Shortreed, PhD1,2
doi : 10.1001/jamapsychiatry.2021.0493
JAMA Psychiatry. 2021;78(7):726-734
Clinical prediction models estimated with health records data may perpetuate inequities.
Kenneth S. Kendler, MD1,2; Henrik Ohlsson, PhD3; Jan Sundquist, MD, PhD3,4,5; Kristina Sundquist, MD, PhD3,4,5
doi : 10.1001/jamapsychiatry.2021.0336
JAMA Psychiatry. 2021;78(7):735-743
Family and genetic approaches have traditionally been used to evaluate our diagnostic concepts. Using a novel method, the family genetic risk score (FGRS), can we validate the genetic architecture of major affective and psychotic disorders in a national Swedish sample?
Katharina Schultebraucks, PhD1,2,3; Karmel W. Choi, PhD4; Isaac R. Galatzer-Levy, PhD5; George A. Bonanno, PhD6
doi : 10.1001/jamapsychiatry.2021.0228
JAMA Psychiatry. 2021;78(7):744-752
Major life stressors, such as loss and trauma, increase the risk of depression. It is known that individuals show heterogeneous trajectories of depressive symptoms following major life stressors, including chronic depression, recovery, and resilience. Although common genetic variation has been associated with depression risk, genomic factors that could help discriminate trajectories of risk vs resilience following adversity have not been identified.
ENIGMA Clinical High Risk for Psychosis Working Group
doi : 10.1001/jamapsychiatry.2021.0638
JAMA Psychiatry. 2021;78(7):753-766
The ENIGMA clinical high risk (CHR) for psychosis initiative, the largest pooled neuroimaging sample of individuals at CHR to date, aims to discover robust neurobiological markers of psychosis risk.
Michael Fairley, PhD1; Keith Humphreys, PhD2,3; Vilija R. Joyce, MS4; Mark Bounthavong, PharmD, PhD4; Jodie Trafton, PhD3,5; Ann Combs, MHA5; Elizabeth M. Oliva, PhD2; Jeremy D. Goldhaber-Fiebert, PhD6; Steven M. Asch, MD, MPH2,7; Margaret L. Brandeau, PhD1; Douglas K. Owens, MS, MD2,6,7
doi : 10.1001/jamapsychiatry.2021.0247
JAMA Psychiatry. 2021;78(7):767-777
Opioid use disorder (OUD) is a significant cause of morbidity and mortality in the US, yet many individuals with OUD do not receive treatment.
Milenna T. van Dijk, PhD1,2; Eleanor Murphy, PhD1,2; Jonathan E. Posner, MD1,3; Ardesheer Talati, PhD1,2; Myrna M. Weissman, PhD1,2,4
doi : 10.1001/jamapsychiatry.2021.0350
JAMA Psychiatry. 2021;78(7):778-787
Three-generation family studies of depression have established added risk of psychopathology for offspring with 2 previous generations affected with depression compared with 1 or none. Because of their rigorous methodology, there are few of these studies, and existing studies are limited by sample sizes. Consequently, the 3-generation family risk paradigm established in family studies can be a critical neuropsychiatric tool if similar transmission patterns are reliably demonstrated with the family history method.
Guillermo Horga, MD, PhD1,2; Kenneth Wengler, PhD1,2; Clifford M. Cassidy, PhD3
doi : 10.1001/jamapsychiatry.2021.0927
JAMA Psychiatry. 2021;78(7):788-789
Gabriela Gan, PhD1; Ren Ma, MSc1; Markus Reichert, PhD1,2,3; Marco Giurgiu, PhD1,2; Ulrich W. Ebner-Priemer, PhD1,2; Andreas Meyer-Lindenberg, MD1; Heike Tost, MD, PhD1
doi : 10.1001/jamapsychiatry.2021.0560
JAMA Psychiatry. 2021;78(7):790-792
Katherine L. Musliner, MPH, PhD1,2; Esben Agerbo, PhD1,2,3; Bjarni J. Vilhj?lmsson, PhD1; Clara Albi?ana, MSc1; Thomas D. Als, PhD2,4; S?ren D. ?stergaard, MD, PhD5,6; Preben B. Mortensen, MD1,2,3
doi : 10.1001/jamapsychiatry.2021.0701
JAMA Psychiatry. 2021;78(7):792-795
Brian P. Marx, PhD1,2; Paula P. Schnurr, PhD3,4; Matthew J. Friedman, MD, PhD4
doi : 10.1001/jamapsychiatry.2021.1123
JAMA Psychiatry. 2021;78(7):795
Delfina Janiri, MD1; Georgios D. Kotzalidis, MD, PhD1; Gabriele Sani, MD1,2
doi : 10.1001/jamapsychiatry.2021.1126
JAMA Psychiatry. 2021;78(7):795-796
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟